The human demyelinating disease multiple sclerosis (MS) is thought to result from an autoimmune response to one or more antigens of the central nervous system (CNS) (1, 2). In the disease model experimental allergic encephalomyelitis (EAE), immunization of susceptible animals with CNS tissue elicits an inflammatory CNS disease that bears some resemblance to human MS (3). T-lymphocyte mediation of EAE is demonstrated by the capacity of antigen-specific T cells to adoptively transfer disease when injected into a syngeneic naive animal (4, 5). An important difference between typical acute EAB and MS relates to the extent of demyelination that occurs. Demyelination is characteristic of MS, yet is scant or absent in many forms of acute EAE (3, 6). Recently, a novel MS-like model of EAE has been described in the common marmoset Callithrix jacchus. C. jacchus EAE is characterized by a relapsing remitting clinical course and by pathologic findings of perivascular inflammation, demyelination, and astrogliosis (7).
Proinflammatory cytokines are thought to participate in tissue damage in EAE (reviewed in ref. 8). Interferon y has been proposed as one cytopathogenic factor. An additional candidate that may act synergistically with interferon y is tumor necrosis factor a (TNF-a). TNF-a is reported to be associated with exacerbations in MS and with pathology in EAE (9) (10) (11) (12) (13) (14) (15) (16) . In rodents, the capacity of T-cell clones to adoptively transfer EAE correlates with their ability to produce TNF-a upon stimulation with myelin antigens-for example, myelin basic protein (MBP) or proteolipid protein (17, 18) . Signs of EAE can be abrogated with antibodies to, or other
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inhibitors of, TNF-a (19) (20) (21) (22) . TNF-a enhances antigeninduced T-cell proliferation (23) , lymphocyte adhesion to microvascular endothelium, and trafficking to the CNS (24) (25) (26) (27) . In vitro, TNF-a may also contribute to oligodendroglial cell death and demyelination (28) (29) (30) (31) (32) . Strategies designed to inhibit this cytokine represent a potential selective approach to the treatment of demyelinating diseases.
Inhibitors of the type IV phosphodiesterase (PDE-IV) suppress the release of TNF-a from macrophages and monocytes (33) (34) (35) (36) , two cell types that express primarily the type IV isoenzyme (37) . This effect is mediated via an increase in the intracellular concentration of cAMP (37) (38) (39) and results from inhibition of transcription of the TNF-a gene and release of TNF-a from its precursor molecule (38, (40) (41) (42) . The selectivity for cytokines of the TNF family is emphasized by the absence of inhibitory effect on interleukin 1. Here, we evaluated the effect of rolipram, a well-characterized selective inhibitor of PDE-IV, on EAE in C. jacchus.
MATERIALS AND METHODS
Animals. C. jacchus marmosets were maintained in a primate colony at the University of California, San Francisco, and were cared for in accordance with the institutional guidelines. Blood (2.5 ml) and cerebrospinal fluid (CSF) (20- At the end of the study, or earlier if required due to severe EAE, animals were sacrificed by exsanguination under ketamine anesthesia. Neuropathologic findings were graded according to the density of monocytic infiltration (perivascular cuffing) in the CNS white matter (+ to + + +) and to the presence or absence of macrophage infiltration associated with demyelination and gliosis.
Biological Measurements. TNF-a was measured in triplicate samples of culture supernatants using the cytotoxicity assay on WEHI 164 cells (43), followed by quantitation of acid phosphatase (44) . A standard curve was constructed in each assay using recombinant human TNF-a (Sigma). Plasma anti-MBP antibody titers were measured by ELISA in 96-well plates coated with 8 ,ug of purified human MBP per well (45), using 100 gl of C. jacchus serum (1:100 dilution) and 100 Al of peroxidase-conjugated anti-monkey IgG (1:500, Sigma). ELISA plates were developed with 100 ,lI of ABTS [2,2'-azinobis(3-ethylbenzthiazolinesulfonic acid)] peroxidase substrate per well (Kirkegaard & Perry Laboratories) and read at 405 nm. Plasma and CSF concentrations of rolipram were measured using an RIA (46) .
Brain levels of TNF-a mRNA were quantitated from 3 mg of fresh frozen white matter taken at autopsy and washed with phosphate-buffered saline to remove blood contaminants. A total RNA fraction was extracted using RNA-zol B (Biotecx Laboratories, Houston). A first strand cDNA was synthetized using 2.5 ,ug of total RNA in a 100-gl reaction mixture containing PCR buffer (Promega), 1.5 mM MgCl2, 1 unit of Moloney murine leukemia virus reverse transcriptase (GIBCO/ BRL), 1 mM dNTP, 25 nM random hexamers, and RNase inhibitor (Pharmacia). Ten microliters of cDNA was used for PCR amplification in a 34-p,l reaction mixture in the presence of PCR buffer, 0.5 mM MgCl2, 1 unit of Taq polymerase (GIBCO), and 0.5 ,uM (each) glyceraldehyde-3-phosphate dehydrogenase (G3PDH) and TNF-a upstream and downstream primers. The sequences of the primers were 5'-GCAATGATC-CCAAAGTAGACCTGCCCAGACT-3' (3' TNF-a), 5'-GAGTGACAAGCCTGTAGCCCATGTTGTAGCA-3' (5' TNF-a), 5'-CATGTGGGCCATGAGGTCCACCAC-3' (3' G3PDH), and 5'-TGAAGGTCGGAGTCAACGGATTT-GGT-3' (5' G3PDH MRI abnormalities were present in both controls at day 17 and day 30 after immunization but in none of the three rolipram-treated animals (Table 1) . Findings early in the course of clinical disease consisted of small, round foci of Gd enhancement on Ti-weighted sequences, indicative of bloodbrain barrier disruption. On subsequent examinations, foci of increased T2-weighted signal, suggestive of edema and/or demyelination, were present. In Fig. 1 , early and late MRI findings in representative control (30-92) and treated animals are shown.
Mononuclear cell CSF pleocytosis was present before and at the onset of clinical signs in the control animals, and pleocytosis persisted until the animals were euthanized (Fig. 2) . In were similar in the treatment and control groups, indicating that rolipram did not suppress development of a humoral response to the administered antigen (Fig. 3) .
Neuropathologic Findings. In control animals, numerous, large (>0.6 mm) inflammatory infiltrates composed of mononuclear cells were found within periventricular white matter of the cerebral hemispheres and posterior and lateral funiculi of the spinal cord (Fig. 4) . By contrast, little or no inflammation was found in rolipram-treated animals even though autopsy was performed on animals euthanized 7-19 days after cessation of treatment (Table 1, Fig. 4 ). Rare periventricular infiltrates of small size (<0.2 mm) were present in two animals, one of whom had clinical signs of EAE and the other in whom CSF pleocytosis was present at the time of sacrifice. The spinal cords of all three rolipram-treated animals, studied with multiple sagittal sections encompassing cervical to lumbar levels, were histologically normal. In controls many demyelinating lesions were present, characterized by macrophage infiltration, extensive and sharply demarcated myelin loss, and gliosis, all features that were uniformly absent from lesions of animals in the treatment group.
Brain Levels of TNF-a mRNA. Compared to controls, TNF-a mRNA levels were reduced in two of the treated animals that showed no clinical signs of EAE (Fig. 5) . The treated animal (13-89) that developed EAE 17 days after cessation of treatment showed a level of TNF-a mRNA similar to that of the untreated controls.
DISCUSSION
Rolipram completely prevented the appearance of clinical signs of EAE following immunization, and this effect was sustained for the entire duration of treatment. The immunization regimen employed results in moderate signs of EAE, beginning 2-4 weeks after immunization, in 100% of C. jacchus (7). Protection from EAE in the treatment group was not due to an effect of the antiemetic odansetron, the carrier dimethyl sulfoxide, repeated handling, or s.c. injections, manipulations that were common to treated and untreated animals. Paraclinical indices confirmed the clinical evidence of a treatment effect. CSF pleocytosis occurred in both control animals but only transiently in a single animal during rolipram treatment. MRI scans were abnormal in controls but normal in the treatment group. These data indicate that rolipram prevented significant disruption of the blood-brain barrier and CNS invasion by inflammatory cells, a conclusion also supported by histologic examination of the CNS.
Rolipram treatment was begun on day 7 following immunization in order to induce an immune response to CNS tissue in treated animals. Antibody responses specific to MBP, indicating sensitization, developed equally in control and treatment groups. These findings suggest that the protective effect of rolipram resulted from interference with events subsequent to the induction of a primary immune response to CNS tissue. This interpretation is also consistent with earlier observations in rodents indicating that inhibition of TNF-a suppresses adoptively transferred EAE but does not prevent the induction of MBP-reactive T cells in actively immunized animals (21) . In C. jacchus, antigen-specific T cells appear to persist during rolipram treatment, as termination of the drug was followed by the appearance of clinical signs of EAE in one animal, by CSF pleocytosis in another, and by autopsy findings of EAE in both.
In release from mononuclear cells (33, (35) (36) (37) . For example, in LPS-stimulated human peripheral blood mononuclear cells rolipram has an IC50 of 130 nM, >500 times lower than that of the nonspecific inhibitor pentoxifylline (35) . The rolipram IC50 found for macrophages from C. jacchus (12 nM) is lower than that reported in mice but similar to that of humans. Based on dose-finding data in C. jacchus, a s.c. dose of 10 mg/kg was employed to test for inhibition of EAE. Side effects of treatment, notably vomiting, were immediate and of short duration (<½/2 hr). Interestingly, rolipram has been evaluated as an antidepressant in several human trials and the most common side effects were nausea and vomiting (47) .
C. jacchus EAE is a unique model for human MS because of the clinical and pathologic similarities between the two conditions. Current data demonstrate that this model can be efficiently employed to evaluate a prospective therapy for MS that may not be testable in non-primate systems. We conclude that inhibition of PDE-IV could have major therapeutic potential, either alone or in combination with other agents that raise intracellular concentrations of cAMP, in the therapy of MS or related disorders.
